Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OxyContin Generics From Endo And Teva Will Include Risk Management Plans

Executive Summary

Risk management programs for Endo's and Teva's generic versions of OxyContin reflect differences in the nature of generic marketing compared to that for branded drugs

You may also be interested in...



Duragesic Risk Management Negotiations Ongoing After FDA Health Advisory

Creation of a risk management plan for Johnson & Johnson's Duragesic and generics could be the next regulatory step for the product after FDA's release of a Public Health Advisory on fentanyl overdoses

Duragesic Risk Management Negotiations Ongoing After FDA Health Advisory

Creation of a risk management plan for Johnson & Johnson's Duragesic and generics could be the next regulatory step for the product after FDA's release of a Public Health Advisory on fentanyl overdoses

Remoxy Time-Release Oxycodone Phase III Trial Planned For Year-End

Pain Therapeutics plans to initiate a Phase III trial for Remoxy, its time-release oxycodone, around year-end

Related Content

UsernamePublicRestriction

Register

PS043632

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel